Metagenomi, Inc.

Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in primary T-cells ABE demonstrated highly specific on-target deamination with no detectable translocations and no significant genomic composition differences ABE triplex editing had no adverse effects on cell viability, expansion, or other measures of cell health EMERYVILLE, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today presented a poster (P0533 Poster Session III) titled “Efficient and specific genome editing with metagenomics-derived base editor for human therapeutic applications” at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress in Rome, Italy. “Base editors are powerful gene editing tools that are able to modify genes through single nucleotide changes, including multiplexed gene editing applications without risk of translocations. Our ABEs display critical attributes necessary for successful multiplexed gene editing with remarkable targetability, efficiency, precision and tolerability,” said Brian C. Thomas, PhD, CEO and founder of Metagenomi. “We remain focused on advancing our base editors for in vivo genome editing programs, while pursuing partnerships to advance ex vivo cell therapy applications.” Today’s poster presentation described the following key advantages of the Metagenomi ABE platform: Targetability: Metagenomi’s ABE is targetable to over 95% of the human genome's base pairs, a significantly wider range of sites than first-generation SpCas9 base editors. This expanded scope provides unparalleled flexibility in addressing complex gene target locations. Efficiency: The ABE platform achieved over 95% reproducible and durable triplex protein knockdown in primary T-cells, confirming its highly efficient application for multiplex gene editing. This platform is also compatible with various non-viral methods of site-specific template-integration in a simultaneous step, including CAR, engineered TCR, and/or regulatory genes leveraging a Metagenomi nuclease. This enables a potent all-in-one editing solution for the development of next-generation cell therapies. Specificity: The ABE demonstrated highly specific on-target deamination with minimum-to-no indel formation. Genome-wide analyses confirmed no detectable translocations and no significant genomic composition differences when compared to unedited cells. This precision minimizes the risk of unintended genetic alterations, positioning the company’s ABE for long-term therapeutic applications. Tolerability: Metagenomi’s ABE triplex protein knockdowns exhibited excellent tolerability in cells, with no adverse effects on cell viability, expansion, or changes in stress-related gene expression observed post-editing. Tolerability is especially critical in multiplex editing of primary T-cells, where maintaining cell health is vital for therapeutic efficacy. About MetagenomiMetagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat associated transposases). Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. For more information, please visit https://​metageno​mi​.co. Cautionary Note Regarding Forward‐​Looking StatementsThis press release contains ​“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as ​“anticipate,” ​“believe,” ​“could,” ​“estimate,” ​“expect,” ​“goal,” ​“intend,” ​“look forward to,” ​“may,” ​“plan,” ​“potential,” ​“predict,” ​“project,” ​“should,” ​“will,” ​“would” and similar expressions, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to conduct IND-enabling studies, make regulatory filings such as INDs, statements concerning the potential of therapies and product candidates, statements concerning the timing of data presentations and publications, and any other statements that are not historical facts. Forward looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in ​“Risk Factors,” in our most recent Form 10-K and our most recent 10-Qs on file with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Investor Contact:Simon Harnest - CIO, SVP Investor Relationssimon@​metagenomi.​co Media Contact:Ashlye Hodge - Communications Managerashlye@​metagenomi.​co

Poster presentation highlights SMART adenine base editors (ABEs)small enough to be packaged into a single adeno-associated virus (AAV) Data demonstrate compact SMART system optimizations allowing fortherapeutically-relevant genome editing EMERYVILLE, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today presented a poster titled “Engineering of compact and efficient adenine base editors from metagenomic derived systems” at the American Institute of Chemical Engineers (AIChE) 7th International Conference on CRISPR Technologies in San Diego, CA. “We are thrilled to share the progress we’ve made with our compact SMART systems,” said Chris Brown, PhD and Head of Discovery at Metagenomi. “Our update highlights the improved efficiency of our SMART platform across multiple targets and cell types. We demonstrated that our SMART nucleases can be engineered into functional base editors within the packaging limits of standard AAV. We believe the improved editing efficiency of these SMART systems will enable pursuit of neuromuscular targets, either on our own or in partnerships.” Metagenomi’s SMART platform potentially addresses a key challenge of in vivo gene editing: efficient delivery of gene editing components to tissues beyond the liver. Currently, AAV is an established approach for delivery to extrahepatic tissues, which is necessary for treating neuromuscular diseases such as Duchenne muscular dystrophy (DMD), familial amyotrophic lateral sclerosis (ALS), and Charcot-Marie-Tooth disease type 1A (CMT1A). Traditional gene editing tools such as SpCas9 exceed the cargo capacity of standard AAV vectors, potentially necessitating the need for dual AAV systems, which may reduce overall editing efficiency, increase required dosages, and complicate the manufacturing process. Metagenomi’s SMART genome editing systems are small enough to be packaged into standard AAV vectors, even when additional effector domains are included for base editing, potentially enabling a differentiated therapeutic approach. Metagenomi has taken a multi-pronged approach to optimizing the SMART platform since its initial discovery (Aliaga Goltsman, Daniela S., et al. “Compact...” Nature Communications, vol. 13, no. 1), including structure-guided engineering enabled through collaboration with Professor David Taylor and his lab at UT Austin (Ocampo, Rodrigo Fregoso, et al. "DNA..." bioRxiv). In addition, Metagenomi has applied advanced artificial intelligence (AI) tools trained on natural SMART enzymes, which was presented at the Cold Spring Harbor Laboratory (CSHL) CRISPR Frontiers conference earlier this year. The AI-driven approach underscores the importance of leveraging multiple cutting-edge techniques to advance next-generation gene editing systems. About MetagenomiMetagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat associated transposases). Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. For more information, please visit https://​metageno​mi​.co. Cautionary Note Regarding Forward‐​Looking StatementsThis press release contains ​“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as ​“anticipate,” ​“believe,” ​“could,” ​“estimate,” ​“expect,” ​“goal,” ​“intend,” ​“look forward to,” ​“may,” ​“plan,” ​“potential,” ​“predict,” ​“project,” ​“should,” ​“will,” ​“would” and similar expressions, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to conduct IND-enabling studies, make regulatory filings such as INDs, statements concerning the potential of therapies and product candidates, statements concerning the timing of data presentations and publications, and any other statements that are not historical facts. Forward looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in ​“Risk Factors,” in our most recent Form 10-K and our most recent 10-Qs on file with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Investor Contact:Simon Harnest - CIO, SVP Investor Relationssimon@​metagenomi.​co Media Contact:Ashlye Hodge - Communications Managerashlye@​metagenomi.​co

NEW YORK, Oct. 8, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Metagenomi investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between February 9 and 13, 2024. Follow the link below to get more information and be contacted by a member of our team: MGX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, Metagenomi introduced itself to investors during its initial public offering as a "genetic medicines company" having a long-standing business relationship with Moderna, one of the leading Covid-19 vaccine companies. Integral to Metagenomi's collaboration with Moderna was the claim that the two companies had entered into a Strategic Collaboration and License Agreement on October 29, 2021, which included multiple four-year research programs and a subsequent licensed product-by-licensed product agreement. Metagenomi completed its initial public offering on February 13, 2024, selling 6.25 million shares at $15 per share. However, less than three months later, on May 1, 2024, Metagenomi announced that it and Moderna had "mutually agreed to terminate their collaboration" agreement. An analyst reported on the announcement, noting that the news was surprising, as was its timing. The analyst also noted that the partnership Metagenomi had with Moderna was a critical part of the core thesis and that losing this partnership during this early stage in development raised more questions than answers. In response to the news, Metagenomi's stock price declined from $7.04 per share on May 1, 2024 to $6.17 per share on May 2, 2024. WHAT'S NEXT? If you suffered a loss in Metagenomi during the relevant time frame, you have until November 25, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 SOURCE Levi & Korsinsky, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED